Verona Pharma PLC, trading as American Depositary Shares on NASDAQ under the ticker VRNA, is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for the treatment of respiratory diseases. The company’s primary focus is on creating first-in-class and best-in-class medicines to improve lung function and quality of life in patients suffering from chronic obstructive pulmonary disease (COPD), cystic fibrosis and other airway conditions.
The company’s lead product candidate, ensifentrine, is a dual phosphodiesterase 3 and 4 inhibitor with bronchodilator and anti-inflammatory properties. Ensifentrine has completed multiple Phase 2 and Phase 3 clinical trials assessing its efficacy and safety as an inhaled therapy, both as a monotherapy and as an add-on to existing standard of care. Verona Pharma continues to work toward regulatory submissions and potential commercialization partnerships in key markets.
Headquartered in London, Verona Pharma operates research and development facilities in both the United Kingdom and the United States. The company leverages collaborations with contract research organizations, clinical trial sites and academic institutions to conduct international studies designed to support regulatory filings with agencies in North America, Europe and other regions. Verona Pharma’s global reach enables it to engage a broad spectrum of respiratory specialists and patient communities.
Under the leadership of Chief Executive Officer Mark Sumeray, Verona Pharma’s management team brings extensive experience in biopharmaceutical development, commercialization and strategic partnerships. The board and executive group guide the company’s efforts to advance its pipeline, secure regulatory milestones and explore business development opportunities aimed at delivering novel treatments for patients with unmet needs in respiratory care.
AI Generated. May Contain Errors.
